Marshall Wace, LLP Acumen Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 89,707 shares of ABOS stock, worth $217,090. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,707Holding current value
$217,090% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding ABOS
# of Institutions
84Shares Held
26.8MCall Options Held
319KPut Options Held
86.3K-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$8.27 Million4.42% of portfolio
-
Franklin Resources Inc San Mateo, CA3.4MShares$8.22 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.63MShares$6.36 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.57 Million0.24% of portfolio
-
Laurion Capital Management LP New York, NY1.9MShares$4.59 Million0.07% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $98M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...